J0791 HCPCS code: Injection, crizanlizumab-tmca, 5 mg
J0791 is the HCPCS Level II code for injection, crizanlizumab-tmca, 5 mg. In 2024 Medicare paid an average of $89.17 per service for J0791 across 63,103 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 160 per day on outpatient hospital claims. Medicare volume fell 2% from 2022 to 2024 (64,064 to 63,103 services). In 2024, about 226 clinicians billed Medicare for J0791 for 136 beneficiaries; Florida, California, Maryland accounted for 73% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2020-07-01 |
| Last action effective | 2020-07-01 |
Who bills J0791 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 226 |
| Medicare beneficiaries | 136 |
| States with claims | 5 |
| Share of services in top 3 states (Florida, California, Maryland) | 73% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0791, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 64,064 | 166 | $112.35 | $89.74 |
| 2023 | 65,745 | 152 | $114.49 | $91.19 |
| 2024 | 63,103 | 136 | $111.95 | $89.17 |
States with the most J0791 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 11,269 | $70.12 |
| California | 7,560 | $84.09 |
| Maryland | 6,647 | $93.80 |
| Texas | 5,671 | $97.44 |
| Virginia | 3,840 | $100.06 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 160 | CMS Policy |
| practitioner claims | 160 | CMS Policy |
What changed for J0791
- 2020-07-01: J0791 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0791?
J0791 is the HCPCS Level II code for injection, crizanlizumab-tmca, 5 mg. Short descriptor: "Inj crizanlizumab-tmca 5mg".
How much does Medicare pay for J0791?
In 2024, the average Medicare payment was $89.17 per service (average allowed $111.95).
Does Medicare cover J0791?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J0791 can be billed per day?
160 on outpatient hospital claims; 160 on practitioner claims (NCCI medically unlikely edits).
Related J07 codes
- J0701 — Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0702 — Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
- J0703 — Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
- J0706 — Injection, caffeine citrate, 5 mg
- J0710 — Injection, cephapirin sodium, up to 1 gm
- J0712 — Injection, ceftaroline fosamil, 10 mg
- J0713 — Injection, ceftazidime, per 500 mg
- J0714 — Injection, ceftazidime and avibactam, 0.5 g/0.125 g
- J0715 — Injection, ceftizoxime sodium, per 500 mg
- J0716 — Injection, centruroides immune f(ab)2, up to 120 milligrams
- J0717 — Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0720 — Injection, chloramphenicol sodium succinate, up to 1 gm
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0791
- Watch J0791 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0791
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.